What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms.
This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of experience spanning global pharmaceuticals, generics, biosimilars and serial entrepreneurship.
In this episode, Robert Wessman covers:
(01:12) Why biologics dominate the future of pharmaceuticals and the urgent need to expand access through biosimilars, with treatment costs reaching up to $100,000 per patient annually
(04:10) Building seven companies including six unicorns, and scaling a global generics business across 80+ countries with over 16,500 employees
(12:32) The seven-pillar framework behind building high-performance culture, including vision setting, team alignment and execution discipline
(18:14) The importance of timing in biotech, and how starting too early or too late in biosimilars can determine success or failure
(38:16) Strategic foresight in action, from anticipating regulatory changes to building one of the largest biosimilars pipelines with over 30 products
This conversation offers a clear, experience-backed perspective on scaling in life sciences, building resilient organisations and making high-impact decisions in complex markets. If you are working in biotech, pharma or leadership, this episode provides practical insights worth applying.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr
TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@life_sciences
Robert Wessman
LinkedIn: https://www.linkedin.com/in/robert-wessman/
Lawrence Rose
LinkedIn: https://www.linkedin.com/in/lawrencerose/
Timestamps:
00:00 Introduction
00:46 The global cost challenge of biologics
01:12 Market dynamics and future of biosimilars
03:11 Origins of building multiple pharma companies
04:10 Scaling Actavis into a global leader
05:22 Repeatable frameworks for building companies
06:53 Execution, culture and operational excellence
10:01 Building Alvotech in Iceland
11:10 Hiring globally and building culture
12:32 The seven pillars of high-performance culture
15:28 Execution and accountability at scale
17:03 Scaling rapidly while maintaining culture
18:14 Timing the biosimilars market
19:27 Fundraising and early-stage selling
22:07 Building partnerships and licensing strategy
24:21 Manufacturing strategy and infrastructure
25:49 Business development and commercial model
27:11 Building global supply chains
28:23 Transitioning leadership roles
30:29 Evolution of CEO skillsets
32:03 AI and the future of work in pharma
34:03 Hiring for high-performance teams
36:33 Managing risk and operational challenges
37:07 Reducing development costs through foresight
38:16 Scaling pipeline strategy
40:25 Patent challenges and market barriers
42:19 Anticipating market shifts in biologics
44:11 Navigating setbacks and industry challenges
45:26 Market dynamics and global pricing pressures
47:08 Why Iceland as a strategic base
50:47 Attracting global talent to Iceland
53:09 Capital markets and disciplined growth
54:40 Risks of overfunding
55:04 Personal story and adversity
58:19 Near-death cycling accident
01:00:30 Recovery and resilience
01:05:55 Impact on mindset and life perspective
#LeadingBeyondTheLab #ARTOTalent #Biotech #Pharmaceuticals #Biosimilars #LifeSciences #Leadership
","author_name":"ARTO Talent"}